Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community

Area of Science:

• Pharmacovigilance and patient safety in drug development.
• Stakeholder collaboration in pharmaceutical risk management.

Background:

• Pharmacovigilance is the monitoring of drug and device safety, involving all stakeholders from development to patient use.
• Patients are the primary source of safety information but rarely lead pharmacovigilance efforts.
• Patient organizations in inherited bleeding disorders are empowered to improve safety monitoring.

Purpose of the Study:

• To highlight the critical role of patients in pharmacovigilance.
• To present recommendations from patient organizations for enhancing drug safety.
• To address challenges in communication and collaboration within the pharmacovigilance network.

Main Methods:

• Review of insights from Hemophilia Federation of America (HFA) and National Hemophilia Foundation (NHF).
• Analysis of stakeholder responsibilities in pharmacovigilance.
• Discussion of a Safety Summit addressing communication gaps.

Main Results:

• Patients possess unique insights into drug benefits and harms.
• Improved communication and patient engagement are crucial for effective pharmacovigilance.
• Recommendations developed to enhance information collection and dissemination.

Conclusions:

• A recommitment to patient safety is urgent given recent incidents and therapeutic advancements.
• Empowering patients and fostering collaboration are essential for robust pharmacovigilance.
• Patient-centered approaches are vital for informed decision-making in drug and device use.